

February 7, 1966

Dr. John F. Monroe  
Associate Medical Director  
The Squibb Institute for Medical Research  
New Brunswick, New Jersey 08903

Dear Dr. Monroe:

First, let me thank you for the information regarding the potency of fluphenazine decanoate. As I indicated, our protocol allowed for the concomitant administration of procyclidine. This was done and was extremely effective in modifying the motor effects of fluphenazine. During the past two weeks, since we have reduced the procyclidine, we have noted an increase in side effects and the apparent clinical efficacy of the compound has been heightened. Eleven patients are now in treatment, and two additional subjects will be entered into the program within the next two weeks.

I am writing today with regard to a different problem. During the past year, we have developed a collaborative relationship with the Department of Psychiatry at the University of Istanbul in Turkey. The Chairman of that Department, Dr. Necmaddin Polvan, is carrying out early clinical drug studies in the populations at his research center and at the local community hospital, the Bakirkoy. He has just written to us that he has undertaken a parallel study with the fluphenazine enanthate. It is my impression that the decanoate form has been produced since the ananthate may have had some problems. Are the two forms clinically equivalent? If not, is fluphenazine decanoate available in Turkey? What limitations will be placed on our results by using two different forms if decanoate is not available in Turkey?

Do studies of this compound in Europe come under the jurisdiction of your office?

Many thanks. *ks.*

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:jmh